Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
magrolimab
Description:
Magrolimab is a monoclonal antibody that targets CD47 and is investigated as an anticancer immunotherapy, particularly for blood cancers.
Primary topic:
Acute Myeloid Leukemia Research (45%)
Related topics:
Acute Myeloid Leukemia Research (45%),
Phagocytosis and Immune Regulation (21%),
Bladder and Urothelial Cancer Treatments (8%)
OpenAlex ID:
keywords/magrolimab
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
2020
·
Mark P. Chao
, Chris H. Takimoto
, et al.
·
Frontiers in Oncology
·
273
PDF
The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results
2019
·
David A Sallman
, Adam S. Asch
, et al.
·
Blood
·
234
Updates on targeted therapies for acute myeloid leukaemia
2021
·
Sabine Kayser
, Mark J. Levis
·
British Journal of Haematology
·
203
PDF
CD47–SIRPα-targeted therapeutics: status and prospects
2022
·
R. Maute
, J. Xu
, et al.
·
Immuno-Oncology Technology
·
200
New directions for emerging therapies in acute myeloid leukemia: the next chapter
2020
·
Naval Daver
, Andrew H. Wei
, et al.
·
Blood Cancer Journal
·
181
PDF
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
2023
·
Naval G. Daver
, Paresh Vyas
, et al.
·
Journal of Clinical Oncology
·
163
PDF
Combining CD47 blockade with trastuzumab eliminates HER2-positive breast cancer cells and overcomes trastuzumab tolerance
2021
·
Rosalynd Upton
, Allison Banuelos
, et al.
·
Proceedings of the National Academy of Sciences
·
139
Magrolimab plus azacitidine vs physician’s choice for untreated TP53 -mutated acute myeloid leukemia: the ENHANCE-2 study
2025
·
Joshua F. Zeidner
, David A. Sallman
, et al.
·
Blood
·
91
PDF
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy
2025
·
Naval Daver
, Paresh Vyas
, et al.
·
Blood
·
90
PDF
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.
2020
·
David Andrew Sallman
, Monzr Al Malki
, et al.
·
Journal of Clinical Oncology
·
86
Immune Checkpoint Inhibition in Acute Myeloid Leukemia and Myelodysplastic Syndromes
2022
·
Yasmin Abaza
, Amer M. Zeidan
·
Cells
·
85
PDF
Current and emerging strategies for management of myelodysplastic syndromes
2020
·
Caner Saygin
, Hetty E. Carraway
·
Blood Reviews
·
74
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
2021
·
Naval Daver
, Marina Konopleva
, et al.
·
Blood
·
72
TP53 Mutations in Acute Leukemias and Myelodysplastic Syndromes: Insights and Treatment Updates
2024
·
Valeria Santini
, Maximilian Stahl
, et al.
·
American Society of Clinical Oncology Educational Book
·
69
PDF
Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives
2024
·
Chenyang Jiang
, Hao Sun
, et al.
·
Frontiers in Oncology
·
66
PDF
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
2022
·
Naval Daver
, Jayastu Senapati
, et al.
·
Blood
·
63
What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms
2021
·
Maria Teresa Voso
, Giulia Falconi
, et al.
·
Blood
·
61
Follicular lymphoma: The long and winding road leading to your cure?
2022
·
Max J. Gordon
, Mitchell R. Smith
, et al.
·
Blood Reviews
·
59
Dual checkpoint blockade of CD47 and LILRB1 enhances CD20 antibody-dependent phagocytosis of lymphoma cells by macrophages
2022
·
Tobias Zeller
, Sebastian Lutz
, et al.
·
Frontiers in Immunology
·
56
The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results
2021
·
David Sallman
, Adam Asch
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
·
56
A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.
2020
·
George A. Fisher
, Nehal J. Lakhani
, et al.
·
Journal of Clinical Oncology
·
56
Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results.
2022
·
Naval Guastad Daver
, Paresh Vyas
, et al.
·
Journal of Clinical Oncology
·
52
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors
2025
·
Cathy Eng
, Nehal J. Lakhani
, et al.
·
Targeted Oncology
·
47
PDF
Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
2021
·
Jan Philipp Bewersdorf
, Amer M. Zeidan
·
Cancers
·
41
PDF
A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients.
2020
·
Nehal J. Lakhani
, Amita Patnaik
, et al.
·
Journal of Clinical Oncology
·
40
Show more works
View as search
Works count:
291
Citation count:
3,763
Year
Topic
Type